SCHEMBL5213865

SCHEMBL5213865

CCCC[Sn](CCCC)(CCCC)c1ccc(C(c2ccccc2)(c2ccccc2)n2ccnc2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 3/20 0.60
CYP11B2 P19099 3/20 0.60
CYP19A1 P11511 10/20 0.47
NR1I2 O75469 2/20 0.47
ADORA3 P0DMS8 2/20 0.47
TBXA2R P21731 2/20 0.47
CCKBR P32239 2/20 0.47
OPRK1 P41145 2/20 0.47
SLC6A3 Q01959 2/20 0.47
KCNH2 Q12809 2/20 0.47
NR1H4 Q96RI1 2/20 0.47
CYP3A4 P08684 2/20 0.47
CYP17A1 P05093 2/20 0.47
MEN1 O00255 1/20 0.47
SLC22A1 O15245 1/20 0.47
KCNN4 O15554 1/20 0.47
GMNN O75496 1/20 0.47
USP2 O75604 1/20 0.47
TRPM2 O94759 1/20 0.47
ABCB11 O95342 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL332630 0.78 CYP11B1 (1.00) CYP11B1CYP11B2CYP19A1NR1I2ADORA3
SCHEMBL25312529 0.77 CYP11B1 (0.73) CYP11B1CYP11B2CYP19A1NR1I2ADORA3
SCHEMBL30698274 0.77 CYP11B1 (0.58) CYP11B1CYP11B2CYP19A1NR1I2ADORA3
Methyl Alcohol SCHEMBL27766624 0.76 CYP11B1 (0.89) CYP11B1CYP11B2CYP19A1NR1I2ADORA3
SCHEMBL5738206 0.75 CYP11B1 (0.80) CYP11B1CYP11B2CYP19A1NR1I2ADORA3
Propionaldehyde SCHEMBL7622939 0.74 CYP11B1 (0.73) CYP11B1CYP11B2CYP19A1NR1I2ADORA3
SCHEMBL12199510 0.73 CYP11B1 (0.89) CYP11B1CYP11B2CYP19A1NR1I2ADORA3
Formaldehyde SCHEMBL27502810 0.73 CYP11B1 (0.89) CYP11B1CYP11B2CYP19A1NR1I2ADORA3
SCHEMBL10896782 0.72 CYP11B1 (0.60) CYP11B1CYP11B2CYP19A1NR1I2ADORA3
SCHEMBL5437850 0.72 CYP11B1 (0.80) CYP11B1CYP11B2CYP19A1NR1I2ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117157303-A Analogs of CDDO-2P-IM and CDDO-3P-IM 三萜系化合物治疗公司 2023-12-01 CN disclosed
US-20230365621-A1 ANALOGS OF CDDO-2P-IM AND CDDO-3P-IM TRITERPENOID THERAPEUTICS INC (US) 2023-11-16 US disclosed
CN-115996925-A Capsid inhibitors for the treatment of HIV 吉利德科学公司 2023-04-21 CN disclosed
EP-2969007-A1 HISTONE DEMETHYLASE INHIBITORS Quanticel Pharmaceuticals Inc (US) 2016-01-20 EP disclosed
WO-2014151945-A1 HISTONE DEMETHYLASE INHIBITORS Quanticel Pharmaceuticals, Inc. (US) 2014-09-25 WO disclosed
EP-1333834-A4 ANTIINFLAMMATION AGENTS AMGEN INC (US) 2007-01-17 EP disclosed
EP-1333834-A2 ANTIINFLAMMATION AGENTS Tularik Inc. (US) 2003-08-13 EP disclosed
WO-2002041843-A2 ANTIINFLAMMATION AGENTS TULARIK INC. (US) 2002-05-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230365621-A1 ANALOGS OF CDDO-2P-IM AND CDDO-3P-IM CDYL2, CYP11B2, HSD17B13 CYP11B1 6/4885CYP11B2 2/4885CYP19A1 429/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.